BioXcel Therapeutics Stock Forecast, Price & News

BioXcel Therapeutics' stock was trading at $29.48 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BTAI stock has increased by 51.3% and is now trading at $44.59.
View which stocks have been most impacted by COVID-19.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for BioXcel Therapeutics.

Wall Street analysts have given BioXcel Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BioXcel Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

BioXcel Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 8th 2021.
View our earnings forecast for BioXcel Therapeutics.

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) issued its quarterly earnings results on Tuesday, November, 17th. The company reported ($1.07) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.80) by $0.27.
View BioXcel Therapeutics' earnings history.

7 brokerages have issued 1-year price objectives for BioXcel Therapeutics' shares. Their forecasts range from $60.00 to $175.00. On average, they anticipate BioXcel Therapeutics' stock price to reach $101.00 in the next year. This suggests a possible upside of 126.5% from the stock's current price.
View analysts' price targets for BioXcel Therapeutics.

BioXcel Therapeutics saw a increase in short interest during the month of October. As of October 30th, there was short interest totaling 2,830,000 shares, an increase of 22.0% from the October 15th total of 2,320,000 shares. Based on an average daily volume of 545,200 shares, the short-interest ratio is currently 5.2 days. Currently, 22.4% of the company's stock are sold short.
View BioXcel Therapeutics' Short Interest.

Some companies that are related to BioXcel Therapeutics include Hutchison China MediTech (HCM), Insmed (INSM), GW Pharmaceuticals (GWPH), TG Therapeutics (TGTX), Sage Therapeutics (SAGE), ChemoCentryx (CCXI), Arena Pharmaceuticals (ARNA), Hypera (HYPMY), Legend Biotech (LEGN), MorphoSys (MOR), FibroGen (FGEN), Apellis Pharmaceuticals (APLS), Deciphera Pharmaceuticals (DCPH), Eidos Therapeutics (EIDX) and Agios Pharmaceuticals (AGIO).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), JD.com (JD), Inseego (INSG), Marvell Technology Group (MRVL), Invitae (NVTA), Tesla (TSLA), Advanced Micro Devices (AMD) and Editas Medicine (EDIT).

(BTAI) raised $60 million in an initial public offering (IPO) on Thursday, March 8th 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets served as the underwriters for the IPO and Canaccord Genuity was co-manager.

BioXcel Therapeutics trades on the NASDAQ under the ticker symbol "BTAI."

BioXcel Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include State Street Corp (5.79%), Artemis Investment Management LLP (4.48%), BlackRock Inc. (3.62%), Victory Capital Management Inc. (2.66%), Logos Global Management LP (2.46%) and Massachusetts Financial Services Co. MA (1.30%). Company insiders that own BioXcel Therapeutics stock include Frank Yocca, Peter Mueller, Richard I Steinhart and Vimal Mehta.
View institutional ownership trends for BioXcel Therapeutics.

BTAI stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Massachusetts Financial Services Co. MA, HighPoint Advisor Group LLC, Wells Fargo & Company MN, LPL Financial LLC, Virtus ETF Advisers LLC, and AQR Capital Management LLC.
View insider buying and selling activity for BioXcel Therapeutics.

BTAI stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., State Street Corp, Artemis Investment Management LLP, Sphera Funds Management LTD., Logos Global Management LP, BlackRock Inc., Charles Schwab Investment Management Inc., and J. Goldman & Co LP. Company insiders that have bought BioXcel Therapeutics stock in the last two years include Frank Yocca, Peter Mueller, Richard I Steinhart, and Vimal Mehta.
View insider buying and selling activity for BioXcel Therapeutics.

Shares of BTAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BTAI stock can currently be purchased for approximately $44.59.

BioXcel Therapeutics has a market capitalization of $1.09 billion. The company earns $-32,970,000.00 in net income (profit) each year or ($2.02) on an earnings per share basis. BioXcel Therapeutics employs 31 workers across the globe.

The official website for BioXcel Therapeutics is www.bioxceltherapeutics.com.

BioXcel Therapeutics' mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The company can be reached via phone at 475-238-6837 or via email at [email protected]